Immunopathology of hyper inflammation in covid-19.

Junjun Wang*

Department of Immunology, Eberhard Karls University of Tubingen, Tubingen, Germany.

Introduction

COVID-19, caused by the novel coronavirus SARS-CoV-2, has presented significant challenges globally, primarily due to its variable clinical manifestations ranging from mild respiratory symptoms to severe hyper inflammatory responses leading to Acute Respiratory Distress Syndrome (ARDS) and multi-organ failure. This essay explores the immunopathological mechanisms underlying hyper inflammation in COVID-19 within the context of Clinical Pathology and Laboratory Medicine.

Viral entry and early immune response

SARS-CoV-2 primarily enters human cells via the Angiotensin-Converting Enzyme 2 (ACE2) receptor, expressed abundantly on respiratory epithelial cells and other tissues such as endothelium and kidneys [1]. Upon entry, the virus triggers an innate immune response characterized by the release of pro-inflammatory cytokines such as Interleukin-6 (IL-6), Tumor Necrosis Factor-Alpha (TNF-α), and Interleukin-1 beta (IL-1β) from infected cells and resident immune cells [2].

In some individuals, especially those with comorbidities or advanced age, the immune response to SARS-CoV-2 becomes dysregulated, leading to a phenomenon known as cytokine storm [3]. This hyper inflammatory state is marked by excessive production of cytokines and chemokines, including IL-6, IL-1β, interferons, and chemokines like CCL2 and CXCL10, resulting in widespread tissue damage [4]. The dysregulation is exacerbated by the activation of immune cells such as macrophages and dendritic cells, which further perpetuate the inflammatory cascade.

Hyper inflammation in severe COVID-19 cases often leads to endothelial dysfunction and microvascular thrombosis. Endothelial cells activated by inflammatory cytokines lose their antithrombotic properties and promote a Procoagulant state, contributing to the development of thrombotic complications observed in critically ill patients [5]. Laboratory findings indicative of this include elevated D-dimer levels, fibrinogen, and markers of endothelial activation like von Willebrand factor and soluble thrombomodulin.

The adaptive immune response in COVID-19 involves T cell-mediated cytotoxicity and B cell antibody production against viral antigens [6]. However, in hyper inflammatory states, there is evidence of T cell exhaustion and dysfunction, characterized by decreased T cell proliferation and increased expression of inhibitory receptors such as PD-1 and CTLA-4 [7]. This phenomenon may contribute to prolonged viral persistence and impaired clearance, further perpetuating inflammation and tissue damage.

Clinical Pathology plays a crucial role in identifying biomarkers that reflect the severity of hyper inflammation in COVID-19 [8]. Besides routine inflammatory markers like C-Reactive Protein (CRP) and procalcitonin, newer biomarkers such as ferritin, IL-6, and Soluble IL-2 Receptor (sIL-2R) have shown promise in predicting disease progression and guiding therapeutic interventions [9]. Laboratory testing also includes assessing coagulation parameters and markers of endothelial dysfunction to monitor thrombotic risk.

Management of hyper inflammation in COVID-19 focuses on immunomodulatory therapies to attenuate cytokine storm and reduce tissue damage. Strategies include the use of corticosteroids like dexamethasone, IL-6 inhibitors such as tocilizumab, and Janus Kinase (JAK) inhibitors like baricitinib, which have shown efficacy in improving clinical outcomes by dampening excessive immune activation [10]. Future research directions involve exploring novel therapeutic targets and optimizing treatment regimens based on individual immune profiles and disease stages.

Conclusion

In conclusion, hyper inflammation in COVID-19 represents a complex interplay of dysregulated immune responses, endothelial dysfunction, and thrombotic complications, all of which contribute to the severity and clinical outcomes of the disease. Understanding the immunopathological mechanisms underlying this hyper inflammatory state is crucial for developing effective diagnostic and therapeutic strategies to mitigate the impact of COVID-19 on global health.

References

1. Hoffmann M, Kleine-Weber H, Kruger N, et al. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. BioRxiv. 2020:2020-01.
2. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395(10229):1033-4.

***Correspondence to:** Junjun Wang, Department of Immunology, Eberhard Karls University of Tubingen, Tubingen, Germany, E-mail: wangjun@gmail.de

***Received:** 02-May-2024, Manuscript No. AACPLM-24-141950; **Editor assigned:** 04-May-2024, PreQC No. AACPLM-24-141950 (PQ); **Reviewed:** 18-May-2024, QC No AACPLM-24-141950; **Revised:** 21-May-2024, Manuscript No. AACPLM-24-141950 (R); **Published:** 03-June-2024, DOI: 10.35841/aacplm-6.3.206*

***Citation:** Wang J. Immunopathology of Hyper inflammation in COVID-19. J Clin Path Lab Med. 2024;6(3):206.*

3. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020; 75(23):2950-73.
4. Zheng HY, Zhang M, Yang CX, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 2020; 17(5):541-3.
5. Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020; 26(10):1636-43.
6. RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021; 384(8):693-704.
7. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506.
8. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020; 71(15):762-8.
9. Tay MZ, Poh CM, Rénia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020; 20(6):363-74.
10. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020 395(10234):1417-8.

Citation: *Wang J. Immunopathology of Hyper inflammation in COVID-19. J Clin Path Lab Med. 2024;6(3):206.*